PAP
KALV

Persistent Asset Partners’s KalVista Pharmaceuticals KALV Stock Holding History

Persistent Asset Partners’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-241
Closed -$32.5K – 211
2025
Q1 		$32.5K Buy
+241
New +$2.46K 0.03% 143

Other funds holding KALV

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Persistent Asset Partners's KALV Position: Q1 2026 in Review

Persistent Asset Partners opened a new position in KalVista Pharmaceuticals (KALV) in Q1 2026: 9,001 shares worth $181K. The stake represents 0.07% of the portfolio and ranks #204 among its holdings. This is a return to the name: Persistent Asset Partners previously reported a position in KALV as recently as Q1 2025.

Persistent Asset Partners first reported a position in KALV in Q4 2024 and has held it in 3 quarters since. The position peaked at $393K in Q1 2025. 183 funds tracked by Wall St. Rank hold KALV as of Q1 2026.

  • Persistent Asset Partners held 9,001 shares of KalVista Pharmaceuticals worth $181K as of Q1 2026.
  • KalVista Pharmaceuticals was a new Persistent Asset Partners position in Q1 2026.
  • KalVista Pharmaceuticals made up 0.07% of Persistent Asset Partners's portfolio in Q1 2026, its #204 holding.
  • Persistent Asset Partners first reported a position in KalVista Pharmaceuticals in Q4 2024 and has held it in 3 quarters since.
  • Persistent Asset Partners's KalVista Pharmaceuticals position peaked at $393K in Q1 2025.
  • 183 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2026.

Based on Persistent Asset Partners's 13F filing for Q1 2026, filed 12 May 2026.